Related Experiment Video
Updated: Mar 14, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.8K
[Focus on molecular imaging in prostate cancer]
1Department of Surgery and Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, États-Unis.
Summary
New PET tracers show promise for diagnosing prostate cancer, addressing limitations of current methods like FDG, NaF, and choline. Further research is needed to establish the best use for each new tracer.
Area of Science:
- Oncology
- Radiology
- Molecular Imaging
Background:
- Prostate cancer is a significant public health concern in France, characterized by heterogeneity.
- There is a critical need for accurate, non-invasive imaging to improve diagnosis, therapy selection, and efficacy assessment.
- Current molecular imaging probes require critical review for clinical application.
Purpose of the Study:
- To critically review molecular imaging probes for prostate cancer.
- To assess tracers currently used or in clinical trials for prostate cancer management.
Main Methods:
- A systematic literature review was conducted using PubMed/MEDLINE.
- Searched for articles in French and English on PET tracers in clinical application for prostate cancer.
Main Results:
- Fluorodeoxyglucose (FDG) has limited performance in prostate cancer.
- NaF and choline are approved in France but have limitations: NaF for bone metastases only, and choline with low sensitivity for lymph node metastases and recurrence with low prostate-specific antigen (PSA).
- Prostate-specific membrane antigen (PSMA)-based tracers show encouraging prospects for initial staging and recurrence detection.
Conclusions:
- Advances in molecular biology have driven the development of metabolic imaging.
- Numerous new tracers are under evaluation for prostate cancer.
- Establishing clear indications for each new tracer is essential.
